TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Physician diagnosis of axial spondyloarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary vascular permeability index (PVPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in clinical symptoms assessed by PANSS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Failing Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PROMIS Physical Functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Steps Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PROMIS Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Consistency of chyme in ascending colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of accordance between endoscopic and histologic assignment of polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in hormonal profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pediatric Logistic Organ Dysfunction Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function as measured by the Mini-Mental Status Examination (MMSE)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Functional independence as measured by the Functional Independence Measure (FIM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in protein synthesis (fractional synthesis rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HPV-16 viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regression or non-regression of the cellular atypia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Phase I Participants Experiencing Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Survival Rate at 2 Years
Endpoint domain: Mortality/survival
Primary endpoint: Hemodynamic markers of cardiovascular risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serotype 6B pneumococcal capsular polysaccharide antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to First Post-op Bowel Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Well Being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Family Well Being - Composite Score Derived From 12 Items
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Total fat free mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum value of HMGB1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve from time 0 extrapolated to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Are Headache Pain Free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Are Most Bothersome Symptom (MBS) Free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Who Have at Least a Confirmed Very Good Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of BIIB091
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve from Time 0 to 24 Hours Post-Dose [AUC(0-24h)] of BIIB091
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Elimination Half-Life (T1/2) of BIIB091
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Creatinine Outcome Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Calculated Glomerular Filtration Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Kidney Injury Molecule-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in PTSD Symptom Scale-I (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HLA-DQ2-tetramer response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: recurrence of cardioembolic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Diarrhea/colitis incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Pigmented Villonodular Synovitis (PVNS) Tumor Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent Change in Pigmented Villonodular Synovitis (PVNS) Tumor Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS) Tumor Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage Change in Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS) Tumor Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 4-week self-reported tobacco abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptance Rate of Early NIPPV Treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Center of Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Activity of the Lower Back (M. Erector Spinae Lumbalis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: occurrence rate of grade IV neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Local tolerability in the anterior nares
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of DPD inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antitumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Intraocular Pressure (IOP) at 1 and 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in Best-corrected Visual Acuity (BCVA) at 1 and 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Difference in Eyes With Adverse Events Between Groups
Endpoint domain: Adverse events/effects
Primary endpoint: relative naproxen bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Abnormal Hematological Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Creatinine Clearance of Aflibercept Plus FOLFIRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Glucose area-under-the-curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma Area Under the Curve (AUC) for Tenofovir Alafenamide (TAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Area Under the Curve (AUC) for Tenofovir (TFV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Total Plasma Concentration (Cmax) for Tenofovir Alafenamide (TAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in overjet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day survival after ICU admission
Endpoint domain: Mortality/survival
Primary endpoint: Attention measured through signal detection parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Egg Reduction Rate (ERR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient comfort during oocyte retrieval
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Forced Expiratory Volume at One Second (FEV1) % Predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Parent Depressive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parent Diabetes Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Duration from oxytocin augmentation initiation to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite of all-cause mortality or HF hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Change in Hamilton Depression Rating Scale 17 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Long-term Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Safety Profile
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum (peak) observed plasma drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum (peak) observed plasma concentration following drug administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve from time zero to infinity (AUC 0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Intensive Care Treatment
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: percentage of time pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Enrollment Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Initiation Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Completion Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Practice Time at Home
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: success rate of fibroblasts culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum insulin icodec concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in VAS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of bococizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of bococizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subject satisfaction with navigation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma concentrations of AVP-786
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in CSFQ-14 Total Score Difference
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recurrence of UTIs
Endpoint domain: Adverse events/effects
Primary endpoint: Fertilization Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Survival without needs of intubation at day 14
Endpoint domain: Mortality/survival
Primary endpoint: Change in organ failure at day 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Analyte Concentration (Cmax) of Bedaquiline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Analyte Concentration-time Curve from Time 0 to 72 Hours (AUC [0-72 hours]) of Bedaquiline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve from Time Zero to the Last Measurable Concentration (AUC [0-last]) of Bedaquiline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve from Time Zero to Infinity (AUC [0-infinity]) of Bedaquiline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bispectral Index (BIS) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight gain management
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in MR grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with histologically confirmed CIN3+ or cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Physical activity level - objective measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of full blown HAE attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Exercise capacity during exercise stress test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise capacity during six-minutes walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food ingestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from Baseline in Cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline in Physical Frailty
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in breast density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Asthma Control Test (ACT) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in prealbumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: safety of infusions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with reversion of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with reversion of ventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of subjects developing EKG pattern diagnostic of Brugada Sd. after provocation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence rate of nutritional risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Heart Failure Somatic Perception Scale Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in patient-reported postoperative expectatives
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Score from Perceived Usefulness scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Score from Perceived Ease of Use scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Score from Pre-Test to Post-Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Volume reduction rate of thyroid nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Diet Induced Thermogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Numerical Rating Scale (NRS) - rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical Rating Scale (NRS) - mobile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor heterogeneity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Identification of tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in angiogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood-brain barrier permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurotoxicity due to radiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety of allogeneic anti-CD19 CAR
Endpoint domain: Adverse events/effects
Primary endpoint: Overall response rate according to RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test of Variables of Attention (TOVA) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iowa gambling task (IGT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foregone Payoff Gambling Task (FPGT) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial Working Memory (SWM) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: digit span score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follow-up attendance of HIV-infected patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of HER2 positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cure of Staph infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recurrence of Staph infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HIV Transmission Risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Engraftment rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to prescribed inhaled corticosteroid regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Discontinuations Due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of tracheal tube cuff pressure exceeding 30 cm H2O
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: K-Trans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent drop in mean SBP at night time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Level of Radioactive Iodine in Tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of Disagreement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: average pain with movement on postoperative day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major adverse cerebro-cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Stride Length Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step Length Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of Motion Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Modified Fatigue Impact Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of Participants with major depressive episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Hamilton Depression Rating Scale (HDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiome flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiome metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BAT oxidative metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BAT triglyceride content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Chemoradiotherapy Patients With Positive Pathologic Response at Week 13
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Radiotherapy Patients With Positive Pathologic Response at Week 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Radiotherapy Patients Failure Free at 5 Years Following Study Entry
Endpoint domain: Mortality/survival
Primary endpoint: Change of bacterial counts on hands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent Change From Baseline Body Weight (Weight Loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood pressure (BP), heart rate (HR), height (Ht) and weight [Wt]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes